InHANSE Institute of Head and Neck Studies and Education Contact Us


 ION study logo

Is ablative radioiodine necessary for low risk differentiated thyroid cancer patients.





Inclusion Criteria

To be eligible, all of the following inclusion criteria must be met:
• Aged 16 years or above.
• Histologically confirmation of differentiated thyroid carcinoma. 
• RO total thyroidectomy (in one or two stages with no residual disease present) within the last 6 months.
• Written informed consent.

Exclusion criteria

• The patient is ineligible if any one of the following exclusion criteria are met:
• pT1a – papillary and Follicular carcinoma which is unifocal and <1cm in size. Also pN1b and M1
• R1 Thyroidectomy
The inclusion and exclusion for this study is extensive.  If you require any more detailed information please contact the study doordinator.


Now Closed
Lead Centre: UCL University College London


Study Coordinator:

IoN Trial Coordinator
Cancer Reasearch UK & UCL Cancer Trials Centre
90 Tottenham Court Road
London W1T 4TJ

Tel: 020 7679 9392
Fax: 020 7679 9871


Charity appeal

Find out more about our £1m Charity appeal for the AcceleraTED cancer Treatment programme.